Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients

Journal of the American College of Cardiology

Volumn 63, Issue 6, 2014, Pages 528-536

  Matsumoto, Yoshihiro ^a   Mori, Yasuo ^b   Kageyama, Shinji ^c   Arihara, Kazuo ^d   Sugiyama, Toshikazu ^e   Ohmura, Hiromichi ^f   Yakushigawa, Toru ^b   Sugiyama, Hatsumi ^e   Shimada, Yasushi ^a   Nojima, Youichi ^a   Shio, Nobuo ^c  

^a SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

^b Shibukawa Clinic   (Japan)

^c Kageyama Urological Clinic   (Japan)

^d Ohtemachi Clinic   (Japan)

^e Sugiyama Veterinary Clinic   (Japan)

^f Sugawara Clinic   (Japan)

Author keywords

cardiovascular and cerebrovascular event; hemodialysis; spironolactone

Indexed keywords

CARDIOVASCULAR AND CEREBROVASCULAR EVENT; HEMODIALYSIS; SPIRONOLACTONE;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HOSPITALIZATION; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SPIRONOLACTONE;

EID: 84893842735     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.056     Document Type: Article

References (39)

1. VI. Causes of death in ESRD Am J Kidney Dis 34 1999 S87 S94
2. D. Marcelli, D. Stannard, F. Conte, P.J. Held, F. Locatelli, and F.K. Port ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States Kidney Int 50 1996 1013 1018 (Pubitemid 26302692)
3. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais for the Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153 (Pubitemid 30051645)
4. J. Schrader, S. Luders, and A. Kulschewski et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES): principal results of a prospective randomized controlled study Stroke 36 2005 1218 1226
5. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003 (Pubitemid 34286536)
6. F. Zannad, M. Kessler, and P. Lehert et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 2006 1318 1324 (Pubitemid 44435184)
7. A.D. Struthers, and T.M. MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res 61 2004 663 670 (Pubitemid 38249465)
8. B. Pitt, F. Zannad, W.J. Remme for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
9. B. Pitt, W. Remme, and F. Zannad et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
10. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
11. A.M. Dorrance, H.L. Osborn, R. Grekin, and R.C. Webb Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats Am J Physiol Regul Integr Comp Physiol 281 2001 R944 R950
12. J.M. Osmond, and A.M. Dorrance 11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia Endocrinology 150 2009 713 719
13. Y. Matsumoto, S. Kageyama, and T. Yakushigawa et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients Cardiology 114 2009 32 38
14. E. Gross, M. Rothstein, S. Dombek, and H.I. Juknis Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients Am J Kidney Dis 46 2005 94 101 (Pubitemid 40848437)
15. P. Saudan, F. Mach, and T. Perneger et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients Nephrol Dial Transplant 18 2003 2359 2363 (Pubitemid 37336825)
16. A.K. Cheung, M.J. Sarnak, and G. Yan et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study Kidney Int 65 2004 2380 2389 (Pubitemid 38670024)
17. S. Nakai, K. Iseki, and N. Itami et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010) Ther Apher Dial 16 2012 483 521
18. P. Stenvinkel, J.J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3 2008 505 521
19. B. Pitt, and R. Saran The role of aldosterone blockade in end-stage renal disease Cardiology 114 2009 30 31
20. R.L. Jamison, P. Hartigan, and J.S. Kaufman et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial JAMA 298 2007 1163 1170 (Pubitemid 47403102)
21. N.J. Cano, D. Fouque, and H. Roth et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study J Am Soc Nephrol 18 2007 2583 2591 (Pubitemid 47378875)
22. G. Eknoyan, G.J. Beck, and A.K. Cheung et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis N Engl J Med 347 2002 2010 2019 (Pubitemid 35461657)
23. R. Rocha, C.L. Martin-Berger, P. Yang, R. Scherrer, J. Delyani, and E. McMahon Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart Endocrinology 143 2002 4828 4836 (Pubitemid 35397623)
24. I. Feria, I. Pichardo, and P. Juarez et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity Kidney Int 63 2003 43 52 (Pubitemid 35463905)
25. E. Perrier, B.G. Kerfant, and N. Lalevee et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction Circulation 110 2004 776 783 (Pubitemid 39096003)
26. Y. Takeda Vascular synthesis of aldosterone: role in hypertension Mol Cell Endocrinol 217 2004 75 79 (Pubitemid 38596631)
27. A. Schafer, D. Fraccarollo, S.K. Hildemann, P. Tas, G. Ertl, and J. Bauersachs Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction Cardiovasc Res 58 2003 655 662 (Pubitemid 36694451)
28. D.C. Schohn, H.A. Jahn, and B.C. Pelletier Dose-related cardiovascular effects of spironolactone Am J Cardiol 71 1993 40A 45A (Pubitemid 23046411)
29. Y. Sun, F.J. Ramires, and K.T. Weber Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion Cardiovasc Res 35 1997 138 147 (Pubitemid 27374751)
30. A. Vukusich, S. Kunstmann, and C. Varela et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients Clin J Am Soc Nephrol 5 2010 1380 1387
31. G. Tsivgoulis, K. Vemmos, and C. Papamichael et al. Common carotid artery intima-media thickness and the risk of stroke recurrence Stroke 37 2006 1913 1916 (Pubitemid 44297751)
32. D.H. O'Leary, J.F. Polak, R.A. Kronmal, T.A. Manolio, G.L. Burke, S.K. Wolfson Jr. for the Cardiovascular Health Study Collaborative Research Group Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults N Engl J Med 340 1999 14 22 (Pubitemid 29024679)
33. M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall, and M. Sitzer Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis Circulation 115 2007 459 467 (Pubitemid 46184197)
34. C.A. Herzog, J.M. Mangrum, and R. Passman Sudden cardiac death and dialysis patients Semin Dial 21 2008 300 307
35. M. Yoshida, J. Ma, and T. Tomita et al. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure Congest Heart Fail 11 2005 12 16
36. E. Milik, E. Szczepanska-Sadowska, W. Maslinski, and A. Cudnoch-Jedrzejewska Enhanced expression of mineralocorticoid receptors in the heart after the myocardial infarct in rats J Physiol Pharmacol 58 2007 745 755
37. R. Sukhija, P. Kakar, V. Mehta, and J.L. Mehta Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension Am J Cardiol 98 2006 544 548 (Pubitemid 44162884)
38. S. Suzuki, T. Ohkusa, and T. Sato et al. Effects of aldosterone on Cx43 gap junction expression in neonatal rat cultured cardiomyocytes Circ J 73 2009 1504 1512
39. A. Santoro, E. Mancini, and R. Gaggi et al. Electrophysiological response to dialysis: the role of dialysate potassium content and profiling Contrib Nephrol 149 2005 295 305 (Pubitemid 43265026)